

ESC Declaration of Interests Report

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias

All experts contributing to the development of ESC Guidelines must adhere to the *ESC Declaration and Management of Conflicts of Interest Policy*, ensuring transparency and ethical integrity throughout the Guidelines development process.

In accordance with this policy, they are required to submit a yearly Declaration of Interests (DOI). Each DOI undergoes a review based on established policy criteria, as defined in the policy's annex 3, enabling continuous assessment and management of potential conflicts of interest.

For this Focused Update, the DOI assessment process began in 2024, evaluating declarations from 2023, and continued in 2025—each year including an assessment of interests declared in the preceding calendar year.

Accordingly, for Task Force members and reviewers, this report includes information declared for years 2023 and 2024.

The latest version of the policy and its annexes can be accessed on the ESC website at www.escardio.org/DOI.

This is a Focused Update of 2019 Guidelines and the DOI assessment criteria applied were the same as those used for the 2019 Guidelines.

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------|---|
| Badimon Lina | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Risk Factors and Prevention MSD : Risk Factors and Prevention Ionis : Risk Factors and Prevention |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Risk Factors and Prevention Ionis : Risk Factors and Prevention |
| Baigent Colin | 2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity UK Medical Research Council Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : Funding provided for the coordination of the EMPA-KIDNEY trial, Chair of Steering Committee |
| | 2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity UK Medical Research Council Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : Funding provided for the coordination of the EMPA-KIDNEY and EASI-KIDNEY trials, Chair of Steering Committee |
| Benn Marianne | 2023 Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - Other - Shares in Novo Nordisk A/S for app. 40,000 EUR. Novo Nordisk A/S produces insulin and obesity medication. |
| | 2024 Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - Other - Shares in Novo Nordisk A/S for app. 40,000 EUR. Novo Nordisk A/S produces insulin and obesity medication. |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|--------------------|---|
| Binder Christoph J | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention SOBI : Risk Factors and Prevention |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Basic Science SOBI : Basic Science Novartis : Risk Factors and Prevention Amgen : Risk Factors and Prevention, Basic Science Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Co-editor Atherosclerosis Vice President, European Atherosclerosis Society (2021-2024) |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-------------------|---|
| Catapano Alberico | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Astra Zeneca : Pharmacology and Pharmacotherapy</p> <p>Daiichi Sankyo : Pharmacology and Pharmacotherapy</p> <p>Novartis : Pharmacology and Pharmacotherapy</p> <p>Pfizer : Pharmacology and Pharmacotherapy</p> <p>Sanofi Aventis : Pharmacology and Pharmacotherapy</p> <p>Menarini : Pharmacology and Pharmacotherapy</p> <p>Amgen Inc : Pharmacology and Pharmacotherapy</p> <p>Merck Sharp & Dohme : Pharmacology and Pharmacotherapy</p> <p>Novo-Nordisk : Pharmacology and Pharmacotherapy</p> <p>Medscape : Pharmacology and Pharmacotherapy</p> <p>Amarin : Pharmacology and Pharmacotherapy</p> <p>Esperion : Pharmacology and Pharmacotherapy</p> <p>PeerVoice : Pharmacology and Pharmacotherapy</p> <p>Ionis Pharmaceutical : Pharmacology and Pharmacotherapy</p> <p>Viartis : Pharmacology and Pharmacotherapy</p> <p>Amryt Pharma : Pharmacology and Pharmacotherapy</p> <p>The Corpus : Pharmacology and Pharmacotherapy</p> <p>Ultragenyx : Pharmacology and Pharmacotherapy</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-------------------|---|
| Catapano Alberico | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Pharmacology and Pharmacotherapy Daiichi Sankyo : Pharmacology and Pharmacotherapy Eli Lilly : Pharmacology and Pharmacotherapy Novartis : Pharmacology and Pharmacotherapy Sanofi Aventis : Pharmacology and Pharmacotherapy Menarini : Pharmacology and Pharmacotherapy Chiesi Pharma : Pharmacology and Pharmacotherapy Merck Sharp & Dohme : Pharmacology and Pharmacotherapy Novo-Nordisk : Pharmacology and Pharmacotherapy Medscape : Pharmacology and Pharmacotherapy Amarin : Pharmacology and Pharmacotherapy Regeneron : Pharmacology and Pharmacotherapy Esperion : Pharmacology and Pharmacotherapy Ionis Pharmaceutical : Pharmacology and Pharmacotherapy Viatris : Pharmacology and Pharmacotherapy Ultragenyx : Pharmacology and Pharmacotherapy |
| De Backer Guy | 2023 Nothing to be declared 2024 Nothing to be declared |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|------------------|--|
| Delgado Victoria | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Chronic Heart Failure Philips : Echocardiography GE Healthcare : Echocardiography Merck Sharp & Dohme : Risk Factors and Prevention Edwards Lifesciences : Valvular Heart Disease</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Astra Zeneca : Research project funded by Astra Zeneca providing an ultraosund system and software for analysis of the data (a bit more than 12000 euros to purchase the material; 2 years= 6K/y) , principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. I am member of AHA I am companion member of PCR</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am senior editor of Circulation - journal of the AHA</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|------------------|--|
| Delgado Victoria | <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Chronic Heart Failure Siemens Healthcare : Cross-Modality and Multi-Modality Imaging Topics Philips : Echocardiography GE Healthcare : Echocardiography Merck Sharp & Dohme : Risk Factors and Prevention Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Astra Zeneca : Research project funded by Astra Zeneca providing an ultraosund system and software for analysis of the data (a bit more than 12000 euros to purchase the material; 2 years= 6K/y) , principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. I am member of AHA I am companion member of PCR</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am senior editor of Circulation - journal of the AHA</p> |
| Fabin Natalia | <p>2023 Nothing to be declared</p> <p>2024 Nothing to be declared</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-----------------------|---|
| FERENCE BRIAN A | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention, Research Methodology Daiichi Sankyo : Risk Factors and Prevention, Research Methodology Eli Lilly : Risk Factors and Prevention, Research Methodology Sanofi Aventis : Risk Factors and Prevention, Research Methodology Novo-Nordisk : Risk Factors and Prevention, Research Methodology Regeron : Risk Factors and Prevention, Research Methodology Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : Mendelian randomization study of lowering LDL by inhibiting PCSK9, Principal Investigator Amgen : Mendelian randomization study of Lp(a), Principal Investigator |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Risk Factors and Prevention |
| GRAHAM IAN MAKLIM | 2023 Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Daiichi Sankyo : Risk Factors and Prevention |
| | 2024 Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Daiichi Sankyo : Risk Factors and Prevention |
| KOSKINAS KONSTANTINOS | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-----------------------|--|
| Koskinas Konstantinos | <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Risk Factors and Prevention Merck Sharp & Dohme : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> |
| Landmesser Ulf | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity German Center of Cardiovascular Research (DZHK)</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Abbott : EXAMINE-CAD Study, Principal Investigator Novartis : Support of clinical study to institution, Principal investigator</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|----------------|--|
| Landmesser Ulf | <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity German Center of Cardiovascular Research (DZHK) Leducq Foundation - Network of excellence in cardiovascular research</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Abbott : Clinical Study, Principal Investigator Merck Sharp & Dohme : Clinical Study, Steering Committee Novartis : Support of clinical study to institution, Principal investigator</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|--------------|---|
| Laufs Ulrich | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity DFG</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) , Acute Coronary Syndromes Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) , Risk Factors and Prevention Daiichi Sankyo : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) , Risk Factors and Prevention Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) , Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Acute Coronary Syndromes Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Boehringer-Ingelheim : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Daiichi Sankyo : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Lilly : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Merck Sharp & Dohme : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amarin : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Daiichi Sankyo : clinical studies, investigator Novartis : clinical studies, investigator Amgen : clinical studies, investigator</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|--------------|--|
| Laufs Ulrich | <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity DFG</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention Daiichi Sankyo : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Acute Coronary Syndromes Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Boehringer-Ingelheim : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Daiichi Sankyo : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Lilly : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Merck Sharp & Dohme : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amarin : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Daiichi Sankyo : clinical studies, investigator Novartis : clinical studies, investigator Amgen : clinical studies, investigator</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------|---|
| Mach Francois | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Cardiology Department</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Amarin : Risk Factors and Prevention Tabuk Pharmaceuticals : Risk Factors and Prevention</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------------|--|
| Mach Francois | <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Wilsdorf Foundation, De Reuter Foundation, Bourgex Fondation, Swiss Cardiology Foundation, Swiss National Scientific Foundation</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Astra Zeneca : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention</p> |
| Mihaylova Borislava | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Barts Charity, UK Bowel Research UK Cancer Research UK National Institute for Health and Care Research, UK</p> <hr/> <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Barts Charity, UK Bowel Research UK Cancer Research UK National Institute for Health and Care Research, UK</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|--------------------|---|
| Nordestgaard Borge | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Copenhagen University Hospital - Herlev and Gentofte</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott : Acute Coronary Syndromes Amgen : Acute Coronary Syndromes Novartis : Acute Coronary Syndromes Lilly : Acute Coronary Syndromes Novo-Nordisk : Acute Coronary Syndromes Amarin : Acute Coronary Syndromes Ionis : Acute Coronary Syndromes Mankind : Acute Coronary Syndromes Ultragenix : Acute Coronary Syndromes Arrowhead : Acute Coronary Syndromes Marea : Acute Coronary Syndromes Esperion : Other</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Astrazeneca : Epidemiological scientific collaboration to fund a post.doc. researcher, Principal investigator</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|--------------------|--|
| Nordestgaard Borge | <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Copenhagen University Hospital - Herlev and Gentofte</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Acute Coronary Syndromes Novartis : Acute Coronary Syndromes Novo-Nordisk : Acute Coronary Syndromes Amarin : Acute Coronary Syndromes Arrowhead : Acute Coronary Syndromes Marea : Acute Coronary Syndromes Esperion : Other</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Astrazeneca : Epidemiological scientific collaboration to fund a post.doc. researcher, Principal investigator</p> |
| Richter Dimitris | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF), Other Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Servier : Risk Factors and Prevention ELPEN : Risk Factors and Prevention Viatris : Risk Factors and Prevention</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. FOUNDING MEMBER OF SCOHRE</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|----------------------------|--|
| Richter Dimitris | <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Amgen : Risk Factors and Prevention Servier : Risk Factors and Prevention Menarini : Risk Factors and Prevention Vianex : Risk Factors and Prevention ELPEN : Risk Factors and Prevention Viatris : Risk Factors and Prevention</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. FOUNDING MEMBER OF SCOHRE</p> |
| Roeters Van Lennep Jeanine | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Dutch Heart Foundation</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : research project to assess patient and health care preferences for optimizing lipid management received by department, PI Novartis : Site investigator for phase 3 trial lipid lowering medication, site investigator Amgen : Site investigator for phase 3 trial lipid lowering medication, site investigator Isis Pharmaceuticals : Site investigator for phase 3 trial lipid lowering medication, site investigator regenx bio : site investigator phase 1 study gene therapy, site investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Member scientific advisory board FH Europe (patient organization)</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Member executive committee European Atherosclerosis Society Member scientific advisory board Dutch Heart Foundation</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-------------------------------|--|
| Roeters Van Lennep Jeanine | <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Dutch Heart Foundation Dutch Research Organisation Thorax Foundation</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : research project to assess patient and health care preferences for optimizing lipid management received by department, PI Amgen : Site investigator for phase 3 trial lipid lowering medication, Site investigator Eli Lilly : Site investigator for phase 3 trial lipid lowering medication, Site investigator Novartis : Site investigator for phase 3 trial lipid lowering medication, Site investigator Isis Pharmaceuticals : Site investigator for phase 3 trial lipid lowering medication, Site investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). co-editor for Atherosclerosis Journal Vice-president European Atherosclerosis Society</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------|--|
| Sabatine Marc | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity American Heart Association</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Research Methodology, Other Astra Zeneca : Research Methodology, Other Beren Therapeutics : Research Methodology, Other Dr. Reddy's Laboratories : Research Methodology, Other</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Abbott : Clinical trials in cardiovascular research , Principal Investigator Amgen : Clinical trials in cardiovascular research , Principal Investigator Astra Zeneca : Clinical trials in cardiovascular research , Principal Investigator Boehringer-Ingelheim : Clinical trials in cardiovascular research , Principal Investigator Daiichi Sankyo : Clinical trials in cardiovascular research , Principal Investigator Novartis : Clinical trials in cardiovascular research , Principal Investigator Pfizer : Clinical trials in cardiovascular research , Principal Investigator Merck Sharp & Dohme : Clinical trials in cardiovascular research , Principal Investigator Ionis : Clinical trials in cardiovascular research , Principal Investigator Anthos Therapeutics : Clinical trials in cardiovascular research , Principal Investigator Saghamos Therapeutics : Clinical trials in cardiovascular research , Principal Investigator Verve Therapeutics : Clinical trials in cardiovascular research , Principal Investigator</p> <p>Employment (including part time) in healthcare industry during the year for which you are declaring. Mass General Brigham/Brigham and Women's Hospital/Harvard Medical School : Chair, TIMI Study Group; Professor of Medicine</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editing fees - LWW >\$100k: Editor, Sabatine MS, ed. Pocket Medicine, 8th ed. Philadelphia: Wolters Kluwer Editor, Sabatine MS, ed.</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------|--|
| Sabatine Marc | Pocket Medicine High-Yield Board Review. 2nd ed. Philadelphia: Wolters Kluwer Editor, Sabatine MS, ed. Pocket Cardiology, 2nd ed. Philadelphia: Wolters Kluwer Speaking fees: North American Thrombosis Foundation - <\$10k Elsevier - <\$10k American Medical Association - \$10-50k Corpus - <\$10k WebMD - <\$10k |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Lippincott, Williams & Wilkins : Other Boehringer-Ingelheim : Research Methodology American Medical Association : Research Methodology Anthos Therapeutics : Research Methodology AMPEL Biosolutions : Research Methodology North American Thrombosis Foundation : Research Methodology PeerReview : Research Methodology PRIME : Research Methodology Amgen : Research Methodology, Other Astra Zeneca : Research Methodology, Other Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Abbott : Clinical trials in cardiovascular research , Principal Investigator Amgen : Clinical trials in cardiovascular research , Principal Investigator Astra Zeneca : Clinical trials in cardiovascular research , Principal Investigator Boehringer-Ingelheim : Clinical trials in cardiovascular research , Principal Investigator Novartis : Clinical trials in cardiovascular research , Principal Investigator Pfizer : Clinical trials in cardiovascular research , Principal Investigator Merck Sharp & Dohme : Clinical trials in cardiovascular research , Principal Investigator Ionis : Clinical trials in cardiovascular research , Principal Investigator Anthos Therapeutics : Clinical trials in cardiovascular research , Principal Investigator Saghmos Therapeutics : Clinical trials in cardiovascular research , Principal Investigator Verve Therapeutics : Clinical trials in cardiovascular research , Principal Investigator |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|----------------|--|
| Sabatine Marc | <p>Marea : Clinical trials in cardiovascular research , Principal Investigator</p> <p>Employment (including part time) in healthcare industry. Mass General Brigham/Brigham and Women's Hospital/Harvard Medical School : Chair, TIMI Study Group; Professor of Medicine</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editing fees - LWW >\$100k: Editor, Sabatine MS, ed. Pocket Medicine, 9th ed. Philadelphia: Wolters Kluwer Editor, Sabatine MS, ed. Pocket Cardiology, 2nd ed. Philadelphia: Wolters Kluwer</p> |
| Tokgozoglulale | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Atrial Fibrillation (AF) Abbott : Risk Factors and Prevention Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Eli Lilly : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Merck Sharp & Dohme : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Amarin : Risk Factors and Prevention Ultragenyx : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Risk Factors and Prevention Merck Sharp & Dohme : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Ionis : Risk Factors and Prevention</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-----------------|--|
| Tokgozoglu Lale | 2023 Membership or affiliation in political or advocacy groups working in the field of cardiology. Past-President European Atherosclerosis Society |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott : Risk Factors and Prevention Amgen : Risk Factors and Prevention Bayer : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Eli Lilly : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Menarini : Risk Factors and Prevention Merck Sharp & Dohme : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Amarin : Risk Factors and Prevention Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Risk Factors and Prevention Merck Sharp & Dohme : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Ionis : Risk Factors and Prevention Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Past-President European Atherosclerosis Society |
| | |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry | |
|-----------------|------------------------------------|---|
| Abela Mark | 2023 | Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Research, Innovation and Development Trust (RIDT) Malta |
| | 2024 | Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Research, Innovation and Development Trust (RIDT) Malta |
| Abreu Ana | 2023 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Risk Factors and Prevention, Pharmacology and Pharmacotherapy Ferrer Internacional : Risk Factors and Prevention, Pharmacology and Pharmacotherapy |
| | 2024 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am Section Editor of Global Heart Journal from WHO (no financial interest) |
| Adamo Marianna | 2023 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Abbott Vascular : Valvular Heart Disease |
| | 2024 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Abbott Vascular : Valvular Heart Disease |
| Aktaa Suleman | 2023 | Nothing to be declared |
| | 2024 | Nothing to be declared |
| Arnaout M Samir | 2023 | Nothing to be declared |
| | 2024 | Nothing to be declared |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-----------------------------|--|
| Asselbergs Folkert | 2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity EU Horizon The Dutch Research Council (NWO) The Netherlands Organisation for Health Research and Development (ZonMw) Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : Implementation of common data model for heart failure care pathway , principal investigator Astra Zeneca : Nudging trial to improve guideline adherence in heart failure, principal investigator |
| | 2024 Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : Data standardisation quality registry, principal investigator Astra Zeneca : Nudging trial to improve guideline adherence, principal investigator |
| Baldini Antonio | 2023 Nothing to be declared |
| | 2024 Nothing to be declared |
| Banerjee Amitava | 2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity National Institute of Health Research Membership or affiliation in political or advocacy groups working in the field of cardiology. British Cardiovascular Society British Society of Heart Failure World Heart Federation South Asian Health Foundation |
| | 2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity NIHR UK Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Board member, World Heart Federation |
| Bani Marjeh Mohammed Yassin | 2023 Nothing to be declared |
| | 2024 Nothing to be declared |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry | |
|------------------------|------------------------------------|--|
| Bekbossynova Makhabbat | 2023 | Nothing to be declared |
| | 2024 | Nothing to be declared |
| Bheleel Osama | 2023 | Nothing to be declared |
| | 2024 | Nothing to be declared |
| Boccarra Franck | 2023 | <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Nouvelle Société Francophone d'Athérosclérose</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Sanofi Aventis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Gilead : Other ViiV Healthcare : Other Boehringer-Ingelheim : Risk Factors and Prevention Servier : Risk Factors and Prevention Merck Sharp & Dohme : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Amarin : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer AG : Atrial Fibrillation (AF)</p> <p>Research funding from healthcare industry received personally by you or an entity controlled by you. Amgen</p> |
| | | |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|------------------|--|
| Boccard Franck | <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Nouvelle Société Francophone d'Athérosclérose</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Sanofi Aventis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Gilead : Other ViiV Healthcare : Other Boehringer-Ingelheim : Risk Factors and Prevention Servier : Risk Factors and Prevention Merck Sharp & Dohme : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Amarin : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer AG : Atrial Fibrillation (AF)</p> <p>Research funding from healthcare industry received personally by you or an entity controlled by you. Amgen</p> |
| Borioni Giuseppe | <p>2023</p> <p>Nothing to be declared</p> <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bristol Myers Squibb : Arrhythmias, General Daiichi Sankyo : Atrial Fibrillation (AF) Boston Scientific : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-------------------|---|
| Boriani Giuseppe | 2024 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Member of the Editorial Board of Acta Cardiologica and European Journal of Internal Medicine |
| Bosevski Marijan | 2023 Nothing to be declared |
| | 2024 Nothing to be declared |
| Boskovic Aneta | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Atrial Fibrillation (AF) Bayer : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy Astra Zeneca : Chronic Heart Failure |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure |
| Brida Margarita | 2023 Nothing to be declared |
| | 2024 Nothing to be declared |
| Brodmann Marianne | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Biotronik, Medtronic, Philips, Cordis, Cook, : Device Therapy |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Peripheral Vascular and Cerebrovascular Disease Abbott Vascular : Peripheral Vascular and Cerebrovascular Disease Cordis : Peripheral Vascular and Cerebrovascular Disease BD BARD : Peripheral Vascular and Cerebrovascular Disease Penumbra : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure |
| Cenko Edina | 2023 Nothing to be declared |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry | |
|----------------------------------|------------------------------------|---|
| Cenko Edina | 2024 | Nothing to be declared |
| Chukhrukidze Archil | 2023 | Nothing to be declared |
| | 2024 | Nothing to be declared |
| Dagres Nikolaos | 2023 | Nothing to be declared |
| | 2024 | Nothing to be declared |
| Degertekin Muzaffer M | 2023 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Interventional Cardiology |
| | 2024 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Interventional Cardiology |
| Dopheide Joern Fredrik | 2023 | Nothing to be declared |
| | 2024 | Nothing to be declared |
| Dos Santos Ferreira Jorge Manuel | 2023 | Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Chronic Heart Failure Merck Sharp & Dohme : Pharmacology and Pharmacotherapy Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Amgen : Pharmacology and Pharmacotherapy Membership or affiliation in political or advocacy groups working in the field of cardiology. Portugal National Leader and Steering Committee member of the following clinical trials: 1. VESALIUS-CV 2. OCEAN(a) Outcomes 3. ESSENCE CS9 4. LIBREXIA-AF |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|----------------------------------|---|
| Dos Santos Ferreira Jorge Manuel | <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Stroke</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Menarini : Hypertension</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate Editor of Portuguese Journal of Cardiology</p> |
| Drexel Heinz | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Other, Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Menarini : Risk Factors and Prevention MedMedia : Risk Factors and Prevention</p> <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention MAW : Risk Factors and Prevention AHS Asian Heart Society : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Daiichi Sankyo : Risk Factors and Prevention</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-----------------------|---|
| Ebenbichler Christoph | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention |
| Fernandez Olmo Rosa | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Risk Factors and Prevention Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen : Risk Factors and Prevention Servier : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Amarin : Risk Factors and Prevention |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------------|---|
| Fernandez Olmo Rosa | <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Risk Factors and Prevention</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen : Risk Factors and Prevention Servier : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Amarin : Risk Factors and Prevention</p> |
| Fras Zlatko | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Slovenian National Research Agency</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Swixx Biopharma : Cardiovascular Disease in Special Populations Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Novo Nordisk : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : Clinical Studies HORIZON and VICTORION-2-P, PI</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------------|--|
| Fras Zlatko | <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Slovenian National Research Agency</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Swixx Biopharma : Cardiovascular Disease in Special Populations Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Novo Nordisk : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : Clinical Studies HORIZON and VICTORION-2-P, PI</p> |
| Gandjbakhch Estelle | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Device Therapy Medtronic : Device Therapy Biotronik : Device Therapy Microport : Device Therapy Abbott : Interventional Cardiology</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biotronik : research grant for academic research on inherited arrhythmia and catheter ablation, investigator Boston Scientific : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Medtronic : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Microport : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------------|---|
| Gandjbakhch Estelle | <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Device Therapy Medtronic : Device Therapy Biotronik : Device Therapy Zoll Medical : Device Therapy Microport : Device Therapy Abbott : Interventional Cardiology Tenaya : Myocardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biotronik : research grant for academic research on inherited arrhythmia and catheter ablation, investigator Boston Scientific : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Medtronic : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Microport : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator</p> |
| Giga Vojislav | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure PharmaSwiss : Risk Factors and Prevention Krka Pharma : Risk Factors and Prevention</p> <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure PharmaSwiss : Risk Factors and Prevention Krka Pharma : Risk Factors and Prevention</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------|--|
| Gorog Diana A | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Janssen-Cilag : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bayer AG : Investigator initiated study, Principal investigator |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Janssen-Cilag : Atrial Fibrillation (AF) Chiesi Pharma : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editor in Chief of Journal of Thrombosis and Thrombolysis |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-----------------------|--|
| Gouni-Berthold Ioanna | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Ultragenyx : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Ionis : My Clinic participates (is a center) in a study with olezarsen, Principal Investigator Novartis : My Clinic participates (is a center) in the HORIZON(a) trial, the CVOT with pelacarsen, Principal Investigator Amgen : My Clinic participates (is a center) in the OCEAN(a) study, the CVOT with olpasiran, Principal Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am an editor in non-ESC publications, an Executive Board Member of the International Atherosclerosis Society and President-Elect of the DACH-Society for Cardiovascular Prevention (dach-praevention.eu)</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-----------------------|--|
| Gouni-Berthold Ioanna | <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Ultragenyx : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Ionis : My Clinic participates (is a center) in a study with olezarsen, Principal Investigator Novartis : My Clinic participates (is a center) in the HORIZON(a) trial, the CVOT with pelacarsen, Principal Investigator Amgen : My Clinic participates (is a center) in the OCEAN(a) study, the CVOT with olpasiran, Principal Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am an editor in non-ESC publications, an Executive Board Member of the International Atherosclerosis Society and President-Elect of the DACH-Society for Cardiovascular Prevention (dach-praevention.eu)</p> |
| Guasti Luigina | <p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Risk Factors and Prevention</p> <p>2024</p> <p>Nothing to be declared</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|--------------------|---|
| Hayrapetyan Hamlet | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension Gedeon Richter : Hypertension Egis Pharma : Risk Factors and Prevention Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Servier : RCT, national coordinator |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension Egis Pharma : Risk Factors and Prevention Krka Pharma : Risk Factors and Prevention Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Acino : Multicenter International Study, Principal Investigator Servier : RCT, Principal investigator |
| Heidecker Bettina | 2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Pfizer Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer, Bayer, Sanofi-Aventis, Novartis, Astra Zeneca : Clinical Skills, Chronic Heart Failure, Acute Heart Failure, Myocardial Disease, Pericardial Disease Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Pfizer : Analysis of biomarkers in blood of patients with amyloidosis; assess risk for adverse cardiovascular events, Principal investigator |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------------|--|
| Heidecker Bettina | <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Pfizer</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer, Bayer, Sanofi-Aventis, Novartis, Astra Zeneca : Clinical Skills , Chronic Heart Failure , Acute Heart Failure , Myocardial Disease , Pericardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Pfizer : Analysis of biomarkers in blood of patients with amyloidosis; assess risk for adverse cardiovascular events, Principal investigator</p> |
| Henkin Yaakov | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>2024</p> <p>Nothing to be declared</p> |
| Henriksen Finn Lund | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Astra Zeneca : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention</p> |
| Heracleous Hera | <p>2023</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Genesis : Risk Factors and Prevention Boehringer-Ingelheim : Training and Education</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-------------------|---|
| Heracleous Hera | 2024 Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Novagem : Myocardial Disease Sanofi Aventis : Risk Factors and Prevention Menarini : Risk Factors and Prevention |
| Ibanez Borja | 2023 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect). |
| | 2024 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect). |
| Ibrahimi Pranvera | 2023 Nothing to be declared |
| | 2024 Nothing to be declared |
| Ivanov Victoria | 2023 Nothing to be declared |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Krka Pharma : Hypertension, Risk Factors and Prevention Zentiva : Risk Factors and Prevention Egis Pharma : Risk Factors and Prevention Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Krka Pharma : Risk Factors and Prevention |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|--------------|---|
| James Stefan | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Wallenberg foundation, Swedish heart and lung foundation</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Elixir : clinical trial, study chair MSD : Clinical trial, trial executive committee Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p> |
| | <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Swedish research council</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Amgen Inc : Clinical trial, Executive committee Merck Sharp & Dohme : Clinical trial, Executive committee New Amsterdam : DSMB committee. Lipid management , DSMB committee Janssen-Cilag : Executive committee, Executive committee</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry | |
|----------------|------------------------------------|---|
| James Stefan | 2024 | Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Board member of the Swedish research council |
| Jegere Sanda | 2023 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF), Cardiovascular Disease in Special Populations Boehringer Ingelheim : Atrial Fibrillation (AF), Chronic Heart Failure Krka Pharma : Risk Factors and Prevention |
| | 2024 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF), Cardiovascular Disease in Special Populations Boehringer Ingelheim : Atrial Fibrillation (AF), Chronic Heart Failure Krka Pharma : Risk Factors and Prevention |
| Juni Peter | 2023 | Nothing to be declared |
| | 2024 | Nothing to be declared |
| Juonala Markus | 2023 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Astra Zeneca : Risk Factors and Prevention Boehringer-Ingelheim : Risk Factors and Prevention |
| | 2024 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Astra Zeneca : Risk Factors and Prevention Boehringer-Ingelheim : Risk Factors and Prevention |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|------------------------------|--|
| Kaluzna-Oleksy Marta Izabela | 2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Polish Medical Research Agency Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Acute Coronary Syndromes Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure |
| | 2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity ABM - Medical Research Agency in Poland Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca, Sanofi, Promed, NovoNordisk : Chronic Heart Failure Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Polish Heart Failure Patients Organization |
| Kiss Robert Gabor | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Atrial Fibrillation (AF) Bayer AG : Atrial Fibrillation (AF) MSD : Atrial Fibrillation (AF) Boehringer-Ingelheim : Chronic Heart Failure Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen Inc : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Novo-Nordisk : Risk Factors and Prevention Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Novartis : Chronic Heart Failure |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|------------------------|--|
| Kiss Robert Gabor | <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Atrial Fibrillation (AF) Bayer AG : Atrial Fibrillation (AF) MSD : Atrial Fibrillation (AF) Boehringer-Ingelheim : Chronic Heart Failure Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen Inc : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Novo-Nordisk : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Astra Zeneca : Chronic Heart Failure</p> |
| Krychtiuk Konstantin A | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Zoll Medical : Acute Cardiac Care Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Amarin : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Daiichi Sankyo : Risk Factors and Prevention Amgen : Risk Factors and Prevention, Other</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. ACC HeartPAC 2022 attendee</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|------------------------|---|
| Krychtiuk Konstantin A | <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Zoll Medical : Acute Cardiac Care Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Amarin : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Daiichi Sankyo : Risk Factors and Prevention Amgen : Risk Factors and Prevention, Other</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. ACC HeartPAC 2022 attendee</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|--------------|--|
| Kubica Jacek | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Ferrer Internacional : Acute Coronary Syndromes, Pharmacology and Pharmacotherapy Astra Zeneca : Chronic Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes Servier : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Pharmacology and Pharmacotherapy Amgen : Pharmacology and Pharmacotherapy Boehringer-Ingelheim : Pharmacology and Pharmacotherapy Novartis : Pharmacology and Pharmacotherapy Sanofi Aventis : Pharmacology and Pharmacotherapy Egis Pharma : Pharmacology and Pharmacotherapy Sanofi Aventis : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Servier : Pharmacology and Pharmacotherapy</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editor in chief of Medical Research Journal (ViaMedica, Poland)</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-------------------|--|
| Kubica Jacek | <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes Servier : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Pharmacology and Pharmacotherapy Amgen : Pharmacology and Pharmacotherapy Boehringer-Ingelheim : Pharmacology and Pharmacotherapy Sanofi Aventis : Pharmacology and Pharmacotherapy Egis Pharma : Pharmacology and Pharmacotherapy</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Servier : Pharmacology and Pharmacotherapy</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editor in chief of Medical Research Journal (ViaMedica, Poland)</p> |
| Kusljugic Zumreta | <p>2023 Nothing to be declared</p> <p>2024 Nothing to be declared</p> |
| Laredj Nadia | <p>2023 Nothing to be declared</p> <p>2024 Nothing to be declared</p> |
| Leening Maarten | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Alzheimer Netherlands Dutch Heart Foundation (DHF)</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Risk Factors and Prevention, Pharmacology and Pharmacotherapy, Training and Education Novartis : Risk Factors and Prevention, Pharmacology and Pharmacotherapy, Training and Education Sanofi Aventis : Risk Factors and Prevention, Pharmacology and Pharmacotherapy, Training and Education</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-----------------|--|
| Leening Maarten | 2023 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Cardiovascular section editor of the European Journal of Epidemiology (Springer). Executive board member of the Dutch Vascular Forum (NVF) - non-profit multidisciplinary cardiovascular CME organisation. Program committee member of the Netherlands Institute for Continuing Cardiovascular Education (CVOI), a non-profit partner institute of the Netherlands Society of Cardiology (NVVC). |
| | 2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Alzheimer Netherlands Dutch Heart Foundation (DHF) Erasmus MC - University Medical Center Rotterdam Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Risk Factors and Prevention, Pharmacology and Pharmacotherapy, Training and Education Novartis : Risk Factors and Prevention, Pharmacology and Pharmacotherapy, Training and Education Sanofi Aventis : Risk Factors and Prevention, Pharmacology and Pharmacotherapy, Training and Education Novo-Nordisk : Risk Factors and Prevention, Pharmacology and Pharmacotherapy, Training and Education Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : Data collection for ESC EUROASPIRE VI in the Netherlands, National Coordinator Novo-Nordisk : Data collection for ESC EUROASPIRE VI in the Netherlands, National Coordinator Sanofi Aventis : Dutch coronary calcium consortium meta-analysis, PI Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Cardiovascular section editor of the European Journal of Epidemiology (Springer). Executive board member of the Dutch Vascular Forum (NVF) - non-profit multidisciplinary cardiovascular CME organisation. Program committee member of the Netherlands Institute for Continuing Cardiovascular Education (CVOI), a non-profit CME partner institute of the Netherlands Society of Cardiology (NVVC). |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|----------------|---|
| Lip Gregory Yh | <p>2023</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellow., Principal Investigator Anthos : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellow., Principal Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Shares in private limited company (a legal separate entity in UK), but no salary/income/personal remuneration received.</p> |
| | <p>2024</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Atrial Fibrillation (AF) Bristol Myers Squibb : Atrial Fibrillation (AF)</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Daiichi Sankyo : Atrial Fibrillation (AF)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bristol Myers Squibb : AF ‘real world’ registry work. Academic, non promotional research work on registries , project supervision Boehringer-Ingelheim : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellows., project supervision Anthos : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellows., project supervision</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial roles in a number of academic journals. Shares in private limited company (a legal separate entity in UK), but no salary/income/personal remuneration received.</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-----------------|--|
| Lorusso Roberto | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abiomed : Acute Heart Failure XENIOS : Device Therapy, Acute Heart Failure</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Device Therapy, Acute Heart Failure, Cardiovascular Surgery Llvanova : Device Therapy, Acute Heart Failure, Cardiovascular Surgery GETINGE : Device Therapy, Acute Heart Failure, Cardiovascular Surgery Eurosets : Device Therapy, Acute Heart Failure, Cardiovascular Surgery</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Medtronic : Research grant on animal experiments for mechanical circulatory support in acute heart failure, Chief investigator Llvanova : Research grant to develop device and system related to extracorporeal circulation, Chief investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editor-in-Chief of the EACTS MultiMedia Manual on Cardio-Thoracic Surgery (Digital and Video Tutorials and Case Reports) Associate Editor of Artificial Organs Associate Editor of the European Heart Journal Case Report</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-----------------|--|
| Lorusso Roberto | <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abiomed : Acute Heart Failure, Cardiovascular Surgery</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Acute Heart Failure, Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure, Cardiovascular Surgery Llvanova : Acute Heart Failure, Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure, Cardiovascular Surgery Eurosets : Acute Heart Failure, Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure, Cardiovascular Surgery XENIOS : Acute Heart Failure, Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure, Cardiovascular Surgery</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Llvanova : Development and tests of a new device for extracorporeal circulation (cardiopulmonary bypass and ECMO), Chief Investigator Medtronic : Research grant to support animal experiment on right ventricular support for acute right ventricular failure and vent-venous ECMO configurations, Chief Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editor-in-Chief of the Multi-Media Manual of Cardio-Thoracic Surgery (by European Association of Cardio-Thoracic Surgery)</p> |
| Maher Vincent | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Other</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Menarini : European Society of Cardiology</p> <hr/> <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Other</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Novartis : European Society of Cardiology</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------|--|
| Mahfoud Felix | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity German Research Foundation</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Chronic Heart Failure Servier : Chronic Heart Failure Bayer AG : Chronic Heart Failure Astra-Zeneca : Chronic Heart Failure Medtronic : Interventional Cardiology Terumo Inc : Interventional Cardiology Recor : Interventional Cardiology Ablative Solutions : Interventional Cardiology INARI : Interventional Cardiology Amgen : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Medtronic : Study site, study site Recor : Study site, study site Ablative Solutions : Study site, study site</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------|---|
| Mahfoud Felix | <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity German Research Foundation</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Chronic Heart Failure Astra-Zeneca : Chronic Heart Failure Merck : Chronic Heart Failure Medtronic : Interventional Cardiology Philips : Interventional Cardiology Recor : Interventional Cardiology Ablative Solutions : Interventional Cardiology INARI : Interventional Cardiology</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Merck : Chronic Heart Failure Medtronic : Interventional Cardiology INARI : Interventional Cardiology</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Medtronic : Study site - Saarland University, Study site - Saarland Universi Recor : Study site - Saarland University, Study site - Saarland Universi Ablative Solutions : Study site - Saarland University, Study site - Saarland Universi</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry | |
|----------------|------------------------------------|--|
| Marketou Maria | 2023 | <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Ferrer Internacional : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Medtronic : Hypertension Servier : Hypertension</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Servier : Hypertension</p> |
| | 2024 | <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Ferrer Internacional : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Medtronic : Hypertension Servier : Hypertension</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Servier : Hypertension</p> |
| Mbarek Nazzi | 2023 | Nothing to be declared |
| | 2024 | Nothing to be declared |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-------------------|---|
| Metra Marco | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novo-Nordisk : Chronic Heart Failure Bayer AG : Chronic Heart Failure Abbott Structural Heart : Chronic Heart Failure Astra Zeneca : Chronic Heart Failure, Acute Heart Failure Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure Roche Diagnostics : Chronic Heart Failure, Acute Heart Failure Edwards Lifesciences : Valvular Heart Disease |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer AG : Chronic Heart Failure Abbott Structural Heart : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure Roche Diagnostics : Chronic Heart Failure, Acute Heart Failure Edwards Lifesciences : Valvular Heart Disease |
| Mirrakhimov Erkin | 2023 Nothing to be declared |
| | 2024 Nothing to be declared |
| Mitchenko Olena | 2023 Nothing to be declared |
| | 2024 Nothing to be declared |
| Moelgaard Inge | 2023 Nothing to be declared |
| | 2024 Nothing to be declared |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-----------------------|--|
| Mohamed Mohamed Selim | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure, Hypertension Novartis : Chronic Heart Failure, Risk Factors and Prevention, Public Health and Health Economics Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Servier : Hypertension Pfizer : Myocardial Disease, Hypertension, Risk Factors and Prevention Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Hamilton Health Sciences, through its Population Health Research : CLEAR SYNERGY (OASIS 9), Principal Investigator |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Chronic Heart Failure Astra Zeneca : Chronic Heart Failure, Acute Coronary Syndromes Novo-Nordisk : Chronic Heart Failure, Risk Factors and Prevention Novartis : Chronic Heart Failure, Risk Factors and Prevention, Public Health and Health Economics Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Servier : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Hypertension Boston Scientific : Interventional Cardiology Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Board member of EAVA (Egyptian Association Of Vascular biology and Atherosclerosis) |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-------------|---|
| Morais Joao | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Acute Coronary Syndromes Bayer Healthcare : Atrial Fibrillation (AF), Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Boehringer-Ingelheim : Chronic Heart Failure Servier : Chronic Heart Failure Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amarin : Risk Factors and Prevention Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Education - I'm organizing every year a local meeting fully supported by industry (www.challengesincardiology.com) Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). President of European and Mediterranean League Against Thrombotic Diseases Associate Editor for "Life" |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Atrial Fibrillation (AF) Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Merck Portugal : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Ferrer Internacional : Risk Factors and Prevention Bial Portela : Risk Factors and Prevention Amarin : Risk Factors and Prevention |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-------------|---|
| Morais Joao | <p>2024</p> <p>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Education - I'm organizing every year a local educational meeting (www.challengesincardiology.com) with support from pharmaceutical companies</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). President of European and Mediterranean League Against Thrombotic Diseases Asssociate Editor for "Life"</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-------------------------|---|
| Mueller Christian Eugen | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</p> <p>Swiss Heart Foundation</p> <p>Swiss National Science Foundation</p> <p>University Hospital Basel</p> <p>University of Basel</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</p> <p>Sphingotec : Acute Heart Failure, PI</p> <p>Medtronic : Detection of cardiac syncope, PI</p> <p>Astra Zeneca : Detection of Heart Failure, PI</p> <p>Boehringer-Ingelheim : Detection of Heart Failure, PI</p> <p>Abbott : Diagnosis of Acute Myocardial Infarction , PI</p> <p>BRAHMS GmbH : Diagnosis of Acute Myocardial Infarction, PI</p> <p>Siemens Healthcare : Diagnosis of Acute Myocardial Infarction, PI</p> <p>Beckman Coulter : Diagnosis of Acute Myocardial Infarction, PI</p> <p>OrthoClinical Diagnostics : Diagnosis of Acute Myocardial Infarction, PI</p> <p>Roche Diagnostics : Diagnosis of Acute Myocardial Infarction, PI</p> <p>quidel : Diagnosis of Acute Myocardial Infarction, PI</p> <p>SpinChip : Diagnosis of Acute Myocardial Infarction, PI</p> <p>LSMI : Diagnosis of Acute Myocardial Infarction, PI</p> <p>Idorsia : Treatment of Acute Myocardial Infarction, PI</p> <p>Novartis : Treatment of CAD, PI</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-------------------------|--|
| Mueller Christian Eugen | <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Swiss Heart Foundation Swiss National Science Foundation University Hospital Basel University of Basel</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Sphingotec : Acute Heart Failure, PI Medtronic : Detection of cardiac syncope, PI Astra Zeneca : Detection of Heart Failure, PI Boehringer-Ingelheim : Detection of Heart Failure, PI Abbott : Diagnosis of Acute Myocardial Infarction , PI BRAHMS GmbH : Diagnosis of Acute Myocardial Infarction, PI Siemens Healthcare : Diagnosis of Acute Myocardial Infarction, PI Beckman Coulter : Diagnosis of Acute Myocardial Infarction, PI OrthoClinical Diagnostics : Diagnosis of Acute Myocardial Infarction, PI Roche Diagnostics : Diagnosis of Acute Myocardial Infarction, PI quidel : Diagnosis of Acute Myocardial Infarction, PI SpinChip : Diagnosis of Acute Myocardial Infarction, PI LSMI : Diagnosis of Acute Myocardial Infarction, PI Idorsia : Treatment of Acute Myocardial Infarction, PI Novartis : Treatment of CAD, PI</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-----------------|--|
| Neubeck Lis | 2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Burdett Trust for Nursing Chief Scientists Office Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Risk Factors and Prevention Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Daiichi Sankyo : Atrial fibrillation screening, Principal Investigator Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Consultant Editor British Journal of Cardiac Nursing |
| | 2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Burdett Trust for Nursing Chief Scientists Office Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Consultant Editor British Journal of Cardiac Nursing |
| Nilsson Lennart | 2023 Nothing to be declared |
| | 2024 Nothing to be declared |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-----------------|---|
| Nissen Steven E | <p>2023</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</p> <p>Mineralys : aldosterone synthase inhibitor, Study Chair</p> <p>Esperion Therapeutics : bempedoic acid outcomes trial, Study Chair of CLEAR Outcomes</p> <p>Eli Lilly : lepodisran and tirzepatide development, Study Chair</p> <p>Astra Zeneca : Nonprescription rosuvastatin, Study Chair</p> <p>New Amsterdam Pharmaceuticals : obicetrapib development, Study Chair</p> <p>Novartis : pelacarsen development, Study Chair</p> <p>Arrowhead Pharmaceuticals : siRNA plozasiran, Study Chair</p> <p>Silence Therapeutics : siRNA zerlasiran, Study Chair</p> <p>Amgen : Study Chair of Glagov Trial, Study Chair of Glagov Trial</p> <p>AbbiVie : TRAVERSE Trial Study Chair (testosterone), TRAVERSE Trial Study Chair</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</p> <p>Editor, Current Cardiology Reports</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-----------------|---|
| Nissen Steven E | <p>2024</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Mineralys : aldosterone synthase inhibitor, Study Chair Cardigan : Aortic Stenosis and Hypertension, Study Chair Esperion Therapeutics : bempedoic acid outcomes trial, Study Chair of CLEAR Outcomes Eli Lilly : lepodisran and tirzepatide development, Study Chair Bristol Myers Squibb : Mavacamten clinical trials, Study Chair and Executive Comm Astra Zeneca : Nonprescription rosuvastatin, Study Chair New Amsterdam Pharmaceuticals : obicetrapib development, Study Chair Novartis : pelacarsen development, Study Chair Arrowhead Pharmaceuticals : siRNA plogasiran, Study Chair Silence Therapeutics : siRNA zerlasiran, Study Chair Amgen : Study Chair of Glagov Trial, Study Chair of Glagov Trial AbbiVie : TRAVERSE Trial Study Chair (testosterone), TRAVERSE Trial Study Chair Crispr Therapeutics : Trial design, Study Chair</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editor, Current Cardiology Reports</p> |
| Nodari Savina | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Vifor International : Chronic Heart Failure Novo-Nordisk : Risk Factors and Prevention</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry | |
|---------------|------------------------------------|---|
| Nodari Savina | 2024 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Chronic Heart Failure Novartis : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Amarin : Risk Factors and Prevention |
| Ostadal Petr | 2023 | Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Czech Health Research Council Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Acute Coronary Syndromes Novartis : Acute Coronary Syndromes Sanofi Aventis : Acute Coronary Syndromes |
| | 2024 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Acute Coronary Syndromes Novartis : Acute Coronary Syndromes Sanofi Aventis : Acute Coronary Syndromes Zentiva : Acute Coronary Syndromes Boehringer-Ingelheim : Acute Heart Failure Abiomed : Acute Heart Failure Xenios/Fresenius : Acute Heart Failure |
| Osto Elena | 2023 | Nothing to be declared |
| | 2024 | Nothing to be declared |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|------------------|---|
| Parhofer Klaus G | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention, Pharmacology and Pharmacotherapy Daiichi Sankyo : Risk Factors and Prevention, Pharmacology and Pharmacotherapy Novartis : Risk Factors and Prevention, Pharmacology and Pharmacotherapy Sanofi Aventis : Risk Factors and Prevention, Pharmacology and Pharmacotherapy Merck Sharp & Dohme : Risk Factors and Prevention, Pharmacology and Pharmacotherapy Ultragenyx : Risk Factors and Prevention, Pharmacology and Pharmacotherapy Swedish Orphan Biovitrum : Risk Factors and Prevention, Pharmacology and Pharmacotherapy Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : Study on effect of Pelacarsen in patients undergoing regular apheresis for elevated lipoprotein(a), Principal Investigator |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Chronic Heart Failure Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Lilly : Risk Factors and Prevention Merck Sharp & Dohme : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Ultragenyx : Risk Factors and Prevention SOBI Swedish Orphan Biovitrum : Risk Factors and Prevention Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : Study on Lipoprotein(a) lowering in patients undergoing apheresis; Topic area: risk factors and prevention, Principal Investigator |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|------------------------|--|
| Pella Daniel | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Pharmacology and Pharmacotherapy Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention, Pharmacology and Pharmacotherapy Novo-Nordisk : Risk Factors and Prevention |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Pharmacology and Pharmacotherapy Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention, Pharmacology and Pharmacotherapy |
| Perez De Isla Leopoldo | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention |
| Pesce Maurizio | 2023 Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Dompe farmaceutici : research on angiogenic peptides and SARS-CoV-2, chief investigator |
| | 2024 Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Dompe Farmaceutici : Testing coagulation effect of peptides mimicking the SARS-CoV-2 spike protein, Project Responsible Chiesi Pharma : Testing of propriatry DDR inhibitors to induce valve cells calcification, Project responsible |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|----------------------|--|
| Petrulioniene Zaneta | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Risk Factors and Prevention Mylan Healthcare / Viatris : Risk Factors and Prevention |
| | 2024 Nothing to be declared |
| Plisiene Jurgita | 2023 Nothing to be declared |
| | 2024 Nothing to be declared |
| Pop Dana | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer : Atrial Fibrillation (AF) Pfizer : Atrial Fibrillation (AF), Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Astra Zeneca : Chronic Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Labormed : Hypertension Viatris : Hypertension, Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Berlin Menarini : Acute Cardiac Care Pfizer : European Society of Cardiology Bayer : History of Cardiology, Chronic Heart Failure, Acute Heart Failure Viatris : Risk Factors and Prevention, Rehabilitation and Sports Cardiology |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|----------|--|
| Pop Dana | <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Johnson & Johnson : Atrial Fibrillation (AF)</p> <p>Pfizer : Atrial Fibrillation (AF), Myocardial Disease, Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure</p> <p>Bayer : Atrial Fibrillation (AF), Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure</p> <p>Gedeon Richter : Atrial Fibrillation (AF), Risk Factors and Prevention</p> <p>Astra Zeneca : Chronic Heart Failure</p> <p>Boehringer-Ingelheim : Chronic Heart Failure</p> <p>Merck Sharp & Dohme : Hypertension</p> <p>Berlin Menarini : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure</p> <p>Amgen : Risk Factors and Prevention</p> <p>Novo-Nordisk : Risk Factors and Prevention</p> <p>Sandoz : Risk Factors and Prevention</p> <p>Krka Pharma : Risk Factors and Prevention</p> <p>Viartis : Risk Factors and Prevention</p> <p>Sun Wave Pharma : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</p> <p>Astra Zeneca : Chronic Heart Failure, Acute Heart Failure</p> <p>Berlin Menarini : Echocardiography</p> <p>Pfizer : European Society of Cardiology</p> <p>Viartis : Risk Factors and Prevention, Rehabilitation and Sports Cardiology</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|--------------------|---|
| Postadzhiyan Arman | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Servier : Hypertension Teva Pharmaceutical Industries : Hypertension Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Menarini : Risk Factors and Prevention |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Servier : Hypertension Teva Pharmaceutical Industries : Hypertension Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Menarini : Risk Factors and Prevention |
| Prescott Eva | 2023 Nothing to be declared |
| | 2024 Nothing to be declared |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|------------------|---|
| Rietzschel Ernst | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Ghent University Research fund</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension Galapagos : Other Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Amarin : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Daiichi Sankyo : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bristol Myers Squibb : Analyses for proteomics of diastolic heart failure, international consortium, Site investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. President of the Belgian Lipid Club / Belgian Atherosclerosis Society (official Belgian representative EAS / IAS)</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|------------------|---|
| Rietzschel Ernst | <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Ghent University Research fund</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Hypertension Galapagos : Other Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Amarin : Risk Factors and Prevention</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Daiichi Sankyo : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bristol Myers Squibb : Analyses for proteomics of diastolic heart failure, international consortium, Site investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. President of the Belgian Lipid Club / Belgian Atherosclerosis Society (official Belgian representative EAS / IAS)</p> |
| Rocca Bianca | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Cancer UK</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Aboca, SRL : Other</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-----------------------------------|---|
| Rocca Bianca | 2023 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial Board of: Assistant Editor Diabetes and Vascular Disease Research Advisory Board: Pharmadvances. Associate Editor: Cardiovascular Drugs and Therapy, Clinical Pharmacology Editorial Board: Bleeding, Thrombosis, and Vascular Biology Associate Editor. Frontiers in Drug Safety and Regulation Section on Cardiovascular Drug Safety Associate Editor for European Cardiology Review Editorial Board European Journal of Preventive Cardiology Editorial Board Journal of Thrombosis and Thrombolysis Editorial Board International Journal of Cardiology |
| | 2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Cancer UK Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer AG : Pharmacology and Pharmacotherapy Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bios Therapy : Substance Based medical devices in obesity, site investigator Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. ISTH, Italian Society of Thrombosis and Haemostasis (SIST), italian society of Pharmacology (SIF), Mediterranean League against Thrombosis |
| Rodriguez Palomares Jose Fernando | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Janssen-Cilag : Myocardial Disease Pfizer : Myocardial Disease Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Pfizer : Cardiac Magnetic Resonance (CMR) |
| | 2024 Nothing to be declared |
| Rossello Francisco Javier | 2023 Nothing to be declared |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------------------|--|
| Rossello Francisco Javier | 2024 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate editor of Heart - https://heart.bmj.com/pages/editorial-board Associate Statistical Editor of Circulation: Cardiovascular Quality and Outcomes - https://www.ahajournals.org/circoutcomes/editorial-board |
| Samadov Fuad | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Novartis : Risk Factors and Prevention |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Risk Factors and Prevention |
| Sannino Anna | 2023 Nothing to be declared |
| | 2024 Nothing to be declared |
| Semb Anne Grete | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Cardiovascular Disease in Special Populations |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Risk Factors and Prevention Finnish Sociesty for Rheumatology : Risk Factors and Prevention, Cardiovascular Disease in Special Populations |
| Shek Aleksandr | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Chronic Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention, Pharmacology and Pharmacotherapy Servier : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Berlin Menarini : Hypertension Abbott : Other Krka Pharma : Risk Factors and Prevention |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-----------------------|---|
| Shek Aleksandr | <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Chronic Heart Failure, Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Risk Factors and Prevention, Pharmacology and Pharmacotherapy Servier : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Berlin Menarini : Hypertension Abbott : Other Krka Pharma : Risk Factors and Prevention</p> |
| Sigurdsson Axel F | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p>2024</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> |
| Siller-Matula Jolanta | <p>2023</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. AOP Orphan Pharmaceuticals : Registry study, PI</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-----------------------|---|
| Siller-Matula Jolanta | <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo : Atrial Fibrillation (AF) Biotronik : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Chiesi Pharma : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Pharmacology and Pharmacotherapy Terumo Inc : Interventional Cardiology Cordis : Interventional Cardiology</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. AOP Orphan Pharmaceuticals : Registry study, PI</p> |
| Socrates Thenral | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Exeltis : Hypertension, Risk Factors and Prevention, Cardiovascular Disease in Special Populations</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Servier : Hypertension</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Roche Diagnostics : Postpartum Hypertension , Biomarker Kits and funding , Principle Investigator</p> <hr/> <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Exeltis : Cardiovascular Disease in Special Populations</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Servier : Other</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|--------------------------|--|
| Speidl Walter Stefan | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Amarin : Risk Factors and Prevention Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Amgen : Research lipid clinic, PI |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Amarin : Risk Factors and Prevention Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Amgen : Research lipid clinic, PI |
| Stefanelli Umberto Maria | 2023 Nothing to be declared |
| | 2024 Nothing to be declared |
| Sudano Isabella | 2023 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Recor Medical : Risk Factors and Prevention |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-----------------|--|
| Sudano Isabella | 2023 Membership or affiliation in political or advocacy groups working in the field of cardiology. Swiss Society of hypertension, Swiss heart Foundation, Swiss Atheosclerosis society, Forum for Tobacco prevention in hospital setting Board Member, all voluntary participation |
| | 2024 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention Recor Medical : Risk Factors and Prevention Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Swiss Society of hypertension, Swiss heart Foundation, Swiss Atheosclerosis society, Forum for Tobacco prevention in hospital setting Board Member, all voluntary participation |
| Tanner Felix C | 2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Swiss Heart Foundation Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Philips : Echocardiography Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Secretary, UEMS Cardiac Section Board, Swiss Institute for Medical Education Board, Swiss Heart Foundation Editorial Board, International Journal of Cardiology Editorial Board, Journal of Clinical Medicine Editorial Board, Swiss Medical Weekly Editorial Board, Cardiovascular Medicine |
| | 2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Swiss Heart Foundation |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|--------------------------|--|
| Tanner Felix C | 2024 Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Secretary, UEMS Cardiac Section Board, Swiss Institute for Medical Education Board, Swiss Heart Foundation Editorial Board, International Journal of Cardiology Editorial Board, Journal of Clinical Medicine Editorial Board, Swiss Medical Weekly |
| TRIKI Faten | 2023 Nothing to be declared 2024 Nothing to be declared |
| van de Borne Philippe | 2023 Nothing to be declared 2024 Nothing to be declared |
| Vesterbekkmo Elisabeth K | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amarin : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen : Rehabilitation and Sports Cardiology Bayer : Rehabilitation and Sports Cardiology Boehringer-Ingelheim : Rehabilitation and Sports Cardiology Novartis : Rehabilitation and Sports Cardiology Sanofi Aventis : Rehabilitation and Sports Cardiology Sanofi Aventis : Risk Factors and Prevention Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of the working group in Prevention, Rehabilitation and Sports cardiology of the Norwegian Society of Cardiology 2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity The Joint Research Committee between St. Olavs Hospital and the Faculty of Medicine and Health Sciences, NTNU Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim : Rehabilitation and Sports Cardiology Novartis : Rehabilitation and Sports Cardiology Sanofi Aventis : Rehabilitation and Sports Cardiology |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------------|--|
| Viigimaa Margus | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Sanofi Aventis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Menarini : Hypertension Novartis : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Amgen : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Sanofi Aventis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Menarini : Hypertension Novartis : Risk Factors and Prevention Novo-Nordisk : Risk Factors and Prevention |
| Visser Laurent | 2023 Nothing to be declared |
| | 2024 Nothing to be declared |
| Weingaertner Oliver | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Pharmacology and Pharmacotherapy Novartis : Pharmacology and Pharmacotherapy Sanofi Aventis : Pharmacology and Pharmacotherapy Daiichi-Sankyo : Pharmacology and Pharmacotherapy |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------------|---|
| Weingaertner Oliver | <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Acute Coronary Syndromes Amgen : Pharmacology and Pharmacotherapy Daiichi Sankyo : Pharmacology and Pharmacotherapy Novartis : Pharmacology and Pharmacotherapy</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Daiichi Sankyo : Pharmacology and Pharmacotherapy</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. I am President if the Germany Society of Lipidology (Lipid-Liga) of which I am also a member of.</p> |
| Wojta Johann | <p>2023 Nothing to be declared</p> <p>2024 Nothing to be declared</p> |
| Zambon Alberto | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen : Pharmacology and Pharmacotherapy Daiichi Sankyo : Pharmacology and Pharmacotherapy Novartis : Pharmacology and Pharmacotherapy Servier : Pharmacology and Pharmacotherapy Sanofi Aventis : Pharmacology and Pharmacotherapy Lilly : Pharmacology and Pharmacotherapy Merck Sharp & Dohme : Pharmacology and Pharmacotherapy Zentiva : Pharmacology and Pharmacotherapy Abbott : Risk Factors and Prevention Imperial College, London : Risk Factors and Prevention Amarin : Risk Factors and Prevention</p> |

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|------------------|--|
| Zambon Alberto | <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Amgen : Pharmacology and Pharmacotherapy</p> <p>Daiichi Sankyo : Pharmacology and Pharmacotherapy</p> <p>Novartis : Pharmacology and Pharmacotherapy</p> <p>Servier : Pharmacology and Pharmacotherapy</p> <p>Sanofi Aventis : Pharmacology and Pharmacotherapy</p> <p>Lilly : Pharmacology and Pharmacotherapy</p> <p>Merck Sharp & Dohme : Pharmacology and Pharmacotherapy</p> <p>Zentiva : Pharmacology and Pharmacotherapy</p> <p>Abbott : Risk Factors and Prevention</p> <p>Imperial College, London : Risk Factors and Prevention</p> <p>Amarin : Risk Factors and Prevention</p> |
| Zeppenfeld Katja | <p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</p> <p>Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</p> <p>Biosense Webster : Investigator initiated research, ventricular arrhythmias, PI</p> <p>2024</p> <p>Nothing to be declared</p> |

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry | |
|--------------------|------------------------------------|---|
| Adamo Marianna | 2023 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Abbott Vascular : Valvular Heart Disease |
| | 2024 | Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Abbott Vascular : Valvular Heart Disease |
| Aktaa Suleman | 2023 | Nothing to be declared |
| | 2024 | Nothing to be declared |
| Asselbergs Folkert | 2023 | Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity EU Horizon The Dutch Research Council (NWO) The Netherlands Organisation for Health Research and Development (ZonMw) Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : Implementation of common data model for heart failure care pathway , principal investigator Astra Zeneca : Nudging trial to improve guideline adherence in heart failure, principal investigator |
| | 2024 | Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Novartis : Data standardisation quality registry, principal investigator Astra Zeneca : Nudging trial to improve guideline adherence, principal investigator |
| Baigent Colin | 2023 | Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity UK Medical Research Council Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : Funding provided for the coordination of the EMPA-KIDNEY trial, Chair of Steering Committee |

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|------------------|---|
| Baigent Colin | <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity UK Medical Research Council</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : Funding provided for the coordination of the EMPA-KIDNEY and EASI-KIDNEY trials, Chair of Steering Committee</p> |
| Borger Michael A | <p>2023</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p> <p>2024</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p> |
| Boriani Giuseppe | <p>2023</p> <p>Nothing to be declared</p> <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bristol Myers Squibb : Arrhythmias, General Daiichi Sankyo : Atrial Fibrillation (AF) Boston Scientific : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> |

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry | |
|------------------|------------------------------------|--|
| Boriani Giuseppe | 2024 | Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Member of the Editorial Board of Acta Cardiologica and European Journal of Internal Medicine |
| Brida Margarita | 2023 | Nothing to be declared |
| | 2024 | Nothing to be declared |
| Byrne Robert | 2023 | Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosensors : Clinical trial activity, Principal investigator Abbott Vascular : Research/educational grant to institution of employment to support fellowship programme, Clinical director Boston Scientific : Research/educational grant to institution of employment to support fellowship programme, Principal investigator Translumina : Research/educational grant to institution of employment to support research nurse for patient outcomes, Principal investigator Membership or affiliation in political or advocacy groups working in the field of cardiology. Member of Irish Heart Attack Audit Governance Committee Member Health Products Regulatory Authority (HPRA; Irish Competent Authority) Advisory Committee on Medical Devices Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Deputy Editor at EuroIntervention Guest Editor at Circulation |
| | 2024 | Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosensors : Clinical trial activity, Principal investigator Boston Scientific : Research grant to institution of employment to support a clinical trial, Principal investigator Abbott Vascular : Research/educational grant to institution of employment to support fellowship programme, Clinical director Translumina : Research/educational grant to institution of employment to support research nurse for patient outcomes, Clinical director |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------------|--|
| Byrne Robert | <p>2024</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Member of Irish Heart Attack Audit Governance Committee Member Health Products Regulatory Authority (HPRA; Irish Competent Authority) Advisory Committee on Medical Devices</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Deputy Editor at EuroIntervention Guest Editor at Circulation</p> |
| Gandjbakhch Estelle | <p>2023</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Device Therapy Medtronic : Device Therapy Biotronik : Device Therapy Microport : Device Therapy Abbott : Interventional Cardiology</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biotronik : research grant for academic research on inherited arrhythmia and catheter ablation, investigator Boston Scientific : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Medtronic : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Microport : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------------|---|
| Gandjbakhch Estelle | <p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific : Device Therapy Medtronic : Device Therapy Biotronik : Device Therapy Zoll Medical : Device Therapy Microport : Device Therapy Abbott : Interventional Cardiology Tenaya : Myocardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biotronik : research grant for academic research on inherited arrhythmia and catheter ablation, investigator Boston Scientific : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Medtronic : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator Microport : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator</p> |
| Heidecker Bettina | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Pfizer</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer, Bayer, Sanofi-Aventis, Novartis, Astra Zeneca : Clinical Skills, Chronic Heart Failure, Acute Heart Failure, Myocardial Disease, Pericardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Pfizer : Analysis of biomarkers in blood of patients with amyloidosis; assess risk for adverse cardiovascular events, Principal investigator</p> |

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|-------------------|---|
| Heidecker Bettina | <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Pfizer</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer, Bayer, Sanofi-Aventis, Novartis, Astra Zeneca : Clinical Skills , Chronic Heart Failure , Acute Heart Failure , Myocardial Disease , Pericardial Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Pfizer : Analysis of biomarkers in blood of patients with amyloidosis; assess risk for adverse cardiovascular events, Principal investigator</p> |
| Hennemuth Anja | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity BMBF Deutsche Forschungsgemeinschaft</p> <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity BMBF Deutsche Forschungsgemeinschaft</p> |
| Ibanez Borja | <p>2023</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p> <p>2024</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p> |

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|--------------|---|
| James Stefan | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Wallenberg foundation, Swedish heart and lung foundation</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Elixir : clinical trial, study chair MSD : Clinical trial, trial executive committee Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. Swedish medical Association, Swedish cardiac society</p> |
| | <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Swedish research council</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Amgen Inc : Clinical trial, Executive committee Merck Sharp & Dohme : Clinical trial, Executive committee New Amsterdam : DSMB committee. Lipid management , DSMB committee Janssen-Cilag : Executive committee, Executive committee</p> |

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry | |
|----------------|------------------------------------|--|
| James Stefan | 2024 | Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Board member of the Swedish research council |
| Juni Peter | 2023 | Nothing to be declared |
| | 2024 | Nothing to be declared |
| Landmesser Ulf | 2023 | <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity German Center of Cardiovascular Research (DZHK)</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Abbott : EXAMINE-CAD Study, Principal Investigator Novartis : Support of clinical study to institution, Principal investigator</p> |

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|----------------|--|
| Landmesser Ulf | <p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity German Center of Cardiovascular Research (DZHK) Leducq Foundation - Network of excellence in cardiovascular research</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Amgen : Risk Factors and Prevention Novartis : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Abbott : Clinical Study, Principal Investigator Merck Sharp & Dohme : Clinical Study, Steering Committee Novartis : Support of clinical study to institution, Principal investigator</p> |
| Lip Gregory Yh | <p>2023</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Boehringer-Ingelheim : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellow., Principal Investigator Anthos : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellow., Principal Investigator</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Shares in private limited company (a legal separate entity in UK), but no salary/income/personal remuneration received.</p> |

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------------|--|
| Lip Gregory Yh | <p>2024</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Pfizer : Atrial Fibrillation (AF) Bristol Myers Squibb : Atrial Fibrillation (AF)</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Daiichi Sankyo : Atrial Fibrillation (AF)</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bristol Myers Squibb : AF 'real world' registry work. Academic, non promotional research work on registries , project supervision Boehringer-Ingelheim : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellows., project supervision Anthos : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellows., project supervision</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial roles in a number of academic journals. Shares in private limited company (a legal separate entity in UK), but no salary/income/personal remuneration received.</p> |
| Mcevoy John William | <p>2023 Nothing to be declared</p> <p>2024 Nothing to be declared</p> |
| Mihaylova Borislava | <p>2023</p> <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Barts Charity, UK Bowel Research UK Cancer Research UK National Institute for Health and Care Research, UK</p> |

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------------|--|
| Mihaylova Borislava | 2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Barts Charity, UK Bowel Research UK Cancer Research UK National Institute for Health and Care Research, UK |
| Moelgaard Inge | 2023 Nothing to be declared <hr/> 2024 Nothing to be declared |
| Neubeck Lis | 2023 Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Burdett Trust for Nursing Chief Scientists Office Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Sanofi Aventis : Risk Factors and Prevention Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Daiichi Sankyo : Atrial fibrillation screening, Principal Investigator Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Consultant Editor British Journal of Cardiac Nursing <hr/> 2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Burdett Trust for Nursing Chief Scientists Office Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Consultant Editor British Journal of Cardiac Nursing |

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry | |
|---------------------------|------------------------------------|---|
| Prescott Eva | 2023 | Nothing to be declared |
| | 2024 | Nothing to be declared |
| Rocca Bianca | 2023 | <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Cancer UK</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Aboca, SRL : Other</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Editorial Board of: Assistant Editor Diabetes and Vascular Disease Research Advisory Board: Pharmadvances. Associate Editor: Cardiovascular Drugs and Therapy, Clinical Pharmacology Editorial Board: Bleeding, Thrombosis, and Vascular Biology Associate Editor. Frontiers in Drug Safety and Regulation Section on Cardiovascular Drug Safety Associate Editor for European Cardiology Review Editorial Board European Journal of Preventive Cardiology Editorial Board Journal of Thrombosis and Thrombolysis Editorial Board International Journal of Cardiology</p> |
| | 2024 | <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Cancer UK</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer AG : Pharmacology and Pharmacotherapy</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bios Therapy : Substance Based medical devices in obesity, site investigator</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. ISTH, Italian Society of Thrombosis and Haemostasis (SISST), Italian Society of Pharmacology (SIF), Mediterranean League against Thrombosis</p> |
| Rossello Francisco Javier | 2023 | Nothing to be declared |

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry | |
|---------------------------|------------------------------------|--|
| Rossello Francisco Javier | 2024 | <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate editor of Heart - https://heart.bmj.com/pages/editorial-board Associate Statistical Editor of Circulation: Cardiovascular Quality and Outcomes - https://www.ahajournals.org/circoutcomes/editorial-board</p> |
| Sannino Anna | 2023 | Nothing to be declared |
| | 2024 | Nothing to be declared |
| Tanner Felix C | 2023 | <p>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity Swiss Heart Foundation</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Philips : Echocardiography</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Secretary, UEMS Cardiac Section Board, Swiss Institute for Medical Education Board, Swiss Heart Foundation Editorial Board, International Journal of Cardiology Editorial Board, Journal of Clinical Medicine Editorial Board, Swiss Medical Weekly Editorial Board, Cardiovascular Medicine</p> |
| | 2024 | <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Swiss Heart Foundation</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Secretary, UEMS Cardiac Section Board, Swiss Institute for Medical Education Board, Swiss Heart Foundation Editorial Board, International Journal of Cardiology Editorial Board, Journal of Clinical Medicine Editorial Board, Swiss Medical Weekly</p> |

Clinical Practice Guidelines Committee 2024-2026 - Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2024.

| Expert | Type of Relationship with Industry |
|---------------------|---|
| Wojakowski Wojciech | 2023 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer Ingelheim : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure, Stroke Abbott Vascular : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Valvular Heart Disease Bristol Myers Squibb : Myocardial Disease Pfizer : Stroke |
| | 2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer Ingelheim : Chronic Heart Failure Abbott Vascular : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Valvular Heart Disease Medtronic : Hypertension Bristol Myers Squibb : Myocardial Disease CroiValve : Valvular Heart Disease |
| Zeppenfeld Katja | 2023 Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD) Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Biosense Webster : Investigator initiated research, ventricular arrhythmias, PI |
| | 2024 Nothing to be declared |